Evidence
Addict Sci Clin Pract. 2024 Jun 18;19(1):50. doi: 10.1186/s13722-024-00479-1.
ABSTRACT
BACKGROUND: Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier.
CASE PRESENTATION: We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a single dose of sublingual buprenorphine/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.
CONCLUSIONS: This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.
PMID:38886826 | DOI:10.1186/s13722-024-00479-1
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
Cool Evidence: Engaging Young People and Students in Real-World Evidence
Real-Time Evidence Search [Psychiatry]
AI Research
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
- Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Buprenorphine Affects the Initiation and Severity of Interleukin Induced Acute Pancreatitis in Mice
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Study protocol for the Treating Opioid Patients' Pain and Sadness (TOPPS) study - A randomized control trial to lower depression and chronic pain interference, and increase care retention among persons receiving buprenorphine
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Establishing a research agenda for the study and assessment of opioid withdrawal
- High-Dose Buprenorphine Initiation: A Scoping Review
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
- Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
- Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022
- Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice
- Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder
- Insomnia symptoms and neurofunctional correlates among adults receiving buprenorphine for opioid use disorder
- Cognitive processing therapy (CPT) versus individual drug counseling (IDC) for PTSD for veterans with opioid use disorder maintained on buprenorphine
- Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder in Canada
- Caring for Hospitalized Adults With Opioid Use Disorder in the Era of Fentanyl: A Review
- Utilization of long-acting injectable monthly depot buprenorphine for opioid use disorder (OUD) in Kentucky, before and after COVID-19 related buprenorphine access policy changes
- Stepped Care for Patients to Optimize Whole Recovery (SC-POWR): An Effectiveness Trial Evaluating a Stepped Care Model for Individuals With Opioid Use Disorder and Chronic Pain
- Healthcare staff's perspectives on long-acting injectable buprenorphine treatment: a qualitative interview study
- Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting
- Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder
- Perceptions around medications for opioid use disorder among a diverse sample of U.S. adults
- The Mobile Overdose Response Program: A mobile, low-threshold opioid use disorder treatment model in Philadelphia
- The Mobile Overdose Response Program: A mobile, low-threshold opioid use disorder treatment model in Philadelphia
- Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians
- Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl
- Piloting a Hospital-Based Rapid Methadone Initiation Protocol for Fentanyl
- Methadone Withdrawal-Induced Psychosis: A Case Report
- Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
- Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada
- Blood pressure response to extended-release naltrexone in heroin and prescription opioid users and its implications for cardiovascular morbidity
- Racial and Ethnic Disparities in Geographic Availability of Buprenorphine
- Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives
- Emerging Trends in Opioid Use Disorder Management: A 6-Year Analysis of Emergency Department Visits, Buprenorphine Prescriptions, and Naloxone Distribution (2016-2021)
- Characterization of peer support services for substance use disorders in 11 US emergency departments in 2020: findings from a NIDA clinical trials network site selection process
- Impact of opioid maintenance therapy in the community on reincarceration in individuals with opioid use disorder-A linked cohort study
- The sociodemographic profile and the challenges associated with treatment and rehabilitation in female heroin users: A case series from Northeast India
- Feasibility of Web-Based Single-Session Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Protocol for a Single-Arm Trial
- Shaping and shifting schemas on supervised injectable opioid treatment: findings from a cross-sectional qualitative study in two German treatment facilities
- Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus
- Two-year Opioid Prescription Trends in Local Sanitary Agency Naples 3 South, Campania Region, Italy. Descriptive Analyses and AI-based Translational Perspectives
- A pilot randomized controlled trial of medication adherence therapy: Psychosocial leverage using a significant other (MAT-PLUS) for individuals on extended-release naltrexone
- The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients
- Incarceration history and opioid use among adults living with HIV and chronic pain: a secondary analysis of a prospective cohort study
- Incarceration history and opioid use among adults living with HIV and chronic pain: a secondary analysis of a prospective cohort study
- Unintended consequences of methadone regulation for opioid use disorder treatment among hospitalized patients
- Neuroimaging of opioid effects in humans across conditions of acute administration, chronic pain therapy, and opioid use disorder
- Alcohol withdrawal and amphetamine co-use in an animal model for attention deficit hyperactivity disorder
- Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration
- Comparison of Treatment Receipt and Hospitalization Among Patients With Stimulant Use Disorder and/or Opioid Use Disorder in the Veterans Health Administration
- Opioid use and risks in liver transplant candidates and recipients
- Clinical and healthcare use outcomes after cessation of long term opioid treatment due to prescriber workforce exit: quasi-experimental difference-in-differences study
- Clinical and healthcare use outcomes after cessation of long term opioid treatment due to prescriber workforce exit: quasi-experimental difference-in-differences study
- A qualitative study of experiences with physical activity among people receiving opioid agonist therapy
- Continuous alcohol withdrawal delirium and physical illness-associated delirium in a man brought to the emergency department after a disaster: A case report
Evidence Blueprint
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
- Patient opinion and acceptance of emergency department buprenorphine/naloxone to-go home initiation packs
- Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis
- Low Dose Buprenorphine Initiation: A Guide for the Inpatient Clinician
- Pain Management in Patients With Opioid Use Disorder on Extended-release Buprenorphine: A Case Report
- Initiation of Extended-release Depot Buprenorphine in a Patient Subject to a Community Treatment Order for Both Antipsychotic and Opioid Agonist Treatments
- Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study
- Low-dose Induction of Buprenorphine in Pregnancy: A Case Series
- Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series
- Kratom use disorder: case reports on successful treatment with home induction of buprenorphine-naloxone
- ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids
- The Perceived Role of Withdrawal in Maintaining Opioid Addiction among Adults with Untreated Opioid Use Disorder: A Survey of Syringe Exchange Program Participants
- Pharmacokinetic-pharmacodynamic analysis of drug liking blockade by buprenorphine subcutaneous depot (CAM2038) in participants with opioid use disorder
- Buprenorphine misinformation and willingness to treat patients with opioid use disorder among primary care-aligned health care professionals
- Precipitated Opioid Withdrawal Treated With Ketamine in a Hospitalized Patient: A Case Report
- Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
- Buprenorphine adherence and illicit opioid use among patients in treatment for opioid use disorder
- The End of the X-waiver: Excitement, Apprehension, and Opportunity
- Opioids in geriatric units in 14 Belgian hospitals: prevalence, dosage and associated factors
- Severe tianeptine withdrawal symptoms managed with medications for opioid use disorder: a case report
- Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation
- Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada
- Buprenorphine: two adolescent case reports of bridging the transmucosal form to the extended-release subcutaneous injectable form
- An acute phase reaction from zoledronate mimicking symptoms seen in opioid withdrawal: a case report
- Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
- Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial
- Adrenal Crisis Masked as Septic Shock in a Patient With Opioid Use Disorder on Buprenorphine
- Higher First 30-Day Dose of Buprenorphine for Opioid Use Disorder Treatment Is Associated With Decreased Mortality
- Buprenorphine Affects the Initiation and Severity of Interleukin Induced Acute Pancreatitis in Mice
- Doing Our Best in a Broken System: The Urgent Need for Expansion of Medication for Opioid Use Disorder Treatments in the United States
- The association of medical providers' attitudes about naloxone and people with opioid use disorder and their self-reported "low-barrier" treatment practices
- Withdrawal catastrophizing scale: initial psychometric properties and implications for the study of opioid use disorder and hyperkatifeia
- Treatment of poppy seed tea misuse with buprenorphine in a telehealth practice: a case series
- Non-overdose acute care hospitalizations for opioid use disorder among commercially-insured adults: a retrospective cohort study
- Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder
- Hospital-based opioid treatment: Expanding and sustaining the model in Texas
- Demographics and Clinical Characteristics of Patients With Opioid Use Disorder and Offered Medication-Assisted Treatment in the Emergency Department
- Study protocol for the Treating Opioid Patients' Pain and Sadness (TOPPS) study - A randomized control trial to lower depression and chronic pain interference, and increase care retention among persons receiving buprenorphine
- Buprenorphine and Opioid Use Disorder Training: Graduate Nursing Curricula Recommendations
- Did the 2021 federal change in the practice guidelines for the administration of buprenorphine for treating opioid use disorder increase buprenorphine prescription dispensing in Medicaid population?
- 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies
- Emergency Department Access to Buprenorphine for Opioid Use Disorder
- Buprenorphine prescribing and treatment accessibility in response to regulation changes due to the COVID-19 public health emergency
- Acute Pain Management for Patients Maintained on Sublingual Buprenorphine as Medication for Opioid Use Disorder
- EPD1504: a novel μ-opioid receptor partial agonist attenuates obsessive-compulsive disorder (OCD)-like behaviors
- The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews
- Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials
- Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation
- Establishing a research agenda for the study and assessment of opioid withdrawal
- High-Dose Buprenorphine Initiation: A Scoping Review
- Characterizing Opioid Withdrawal Experiences and Consequences Among a Community Sample of People Who Use Opioids
- Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada
- Characterizing Acute and Postsurgical Pain Management in Patients Receiving Buprenorphine or Buprenorphine/naloxone
- Missed Opportunities: Substance Use Hotline Operator Uncertainty of State Buprenorphine Prescribing via Telemedicine
- Availability and Opportunities for Expansion of Buprenorphine for the Treatment of Opioid Use Disorder
- Associations between stimulant use and return to illicit opioid use following initiation onto medication for opioid use disorder
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Protocol for the development of a consensus practice guideline To address clinical and regulatory barriers to buprenorphine dispensing in community pharmacy
- Health care use and cost of treatment for adolescents and young adults with opioid use disorder
- Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
- Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial
- A population-based time-series analysis of opioid agonist treatment dispensed during pregnancy
- Urine drug testing among Medicaid enrollees initiating buprenorphine treatment for opioid use disorder within 9 MODRN states